Advertisement

Topics

Trio Health Reports Rapid Increase in Non-Start Rates for Hepatitis C Treatment Predominantly Due to Coverage Denials

16:05 EST 7 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Interim findings from 15,000-patient study show increasing denials that are at odds with policy and legal precedent Full data to be reviewed in presentation/webcast on Wednesday, March 8 at 12:15 EST Trio Hea...

Other Sources for this Article

For Trio Health
Investors:
Brian Korb, 646-378-2923
bkorb@troutgroup.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

NEXT ARTICLE

More From BioPortfolio on "Trio Health Reports Rapid Increase in Non-Start Rates for Hepatitis C Treatment Predominantly Due to Coverage Denials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...